Trial Profile
An open label exploratory analysis of blood, stool and the histological and immunological changes of the colonic mucosa during treatment with tofacitinib for moderate to severe ulcerative colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Tofa-histo
- 23 Nov 2020 Status changed to completed.
- 13 Oct 2020 Results of interim analysis n=32, presented at the 28th United European Gastroenterology Week
- 07 Oct 2017 New trial record